ArticleKidney3602026
Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter 2 Inhibitors versus Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
key pointsThe risk of diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors among patients with CKD stages 3-4 and type 2 diabetes is not well established. We found that the overall incidence of hospitalization with diabetic ketoacidosis remained low among sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists initiators with CKD stages 3-4 and type 2 diabetes. sodium-glucose cotransporter 2 inhibitors was associated with a 40% higher risk of hospitalization with diabetic ketoacidosis compared with glucagon-like peptide-1 receptor agonists initiation.
backgroundsodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective in managing CKD and type 2 diabetes (T2D). However, there are concerns about an increased risk of diabetic ketoacidosis (DKA) associated with the use of SGLT2i, particularly in patients with CKD.
methodsThe is a population-based, new-user, active comparator cohort study comparing SGLT2i versus GLP-1 RA initiators using three US health care databases: Optum's deidentified Clinformatics Data Mart (2014-2024), Merative MarketScan (2014-2022), and Medicare Fee-for-Service (2014-2020). The exposure is initiation of either SGLT2i or GLP-1 RA, defined as a new prescription without prior use in 365 days. The primary outcome was hospitalization with DKA identified using inpatient International Classification of Diseases, Ninth/Tenth Revision codes. Incidence rates, rate differences, and hazard ratios were calculated.
resultsAfter 1:1 propensity score matching, the study population included 143,858 patients, 71,929 in the SGLT2i arm, and 71,929 in the GLP-1 RA arm. The mean age (SD) was 71.28 (8.16) years, and 48.8% were female. Patients initiating SGLT2i had higher risk of hospitalization with DKA compared with GLP-1 RA initiators (incidence rate 4.37 versus 3.13 events per 1000 person-years; rate differences 1.23 [95% confidence interval, 0.54 to 1.92]; hazard ratios 1.40 [95% confidence interval, 1.16 to 1.68]). The number needed to harm was 813 per 1000 person-years for SGLT2i compared with GLP-1 RA initiation. Results remained consistent in subgroup analyses stratified by age (younger than 70 versus 70 years or older), sex, body mass index (<30 versus ≥30 kg/m 2 ), frailty status, baseline cardiovascular disease, diabetic retinopathy, hyperglycemia, metformin use, and insulin use.
conclusionsThe incidence rate of DKA among SGLT2i and GLP-1 RA initiators remained low overall. However, SGLT2i use was associated with a 40% increased risk of hospitalization with DKA compared with GLP-1 RA use among patients with CKD stages 3-4 and T2D. Clinicians should remain vigilant when monitoring patients with CKD and T2D treated with SGLT2i.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.